California is currently home to 5600 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/07/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Focal Epilepsy
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
Recruiting
Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/07/2025
Locations: UC Davis Health - UC Davis Health Midtown Ambulatory Care Center, Sacramento, California
Conditions: Congenital Myasthenic Syndrome
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Recruiting
Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Primary Mediastinal Large B-cell Lymphoma (PMBCL), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Transformed Follicular Lymphoma (tFL), Follicular Lymphoma Grade 3B, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma, DLBCL Arising From Follicular Lymphoma, DLBCL, Diffused Large B Cell Lymphoma, DLBCL NOS
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Recruiting
The primary objective of this study is to: * Evaluate the safety and tolerability of AMG 305 in adult participants * Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose * Determine the recommended phase 2 dose (RP2D)
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/07/2025
Locations: City of Hope National Medical Center, Duarte, California
Conditions: Advanced Solid Tumors
Comparison of Uncomplicated Candidemia Therapy Duration in Children
Recruiting
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those... Read More
Gender:
ALL
Ages:
Between 120 days and 18 years
Trial Updated:
05/07/2025
Locations: Children's Hospital of Orange County, Orange, California
Conditions: Invasive Candidiasis
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Recruiting
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.
Gender:
MALE
Ages:
1 year and above
Trial Updated:
05/07/2025
Locations: Stanford School of Medicine /Division of Neuromuscular Medicine, Palo Alto, California
Conditions: Duchenne Muscular Dystrophy
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Recruiting
This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of California San Diego, La Jolla, California
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Recruiting
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients must have confirmed germline or somatic select HRR alterations. Germline and somatic mutation testing will be performed as part of commercially available CLIA assays and will be validated on a uniform platform centrally all... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of California San Diego - Moores Cancer Center, La Jolla, California
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Kind Minds Program for Youth With Anxiety and Depression
Recruiting
Rates of anxiety and depression in youth are substantial, causing a major unmet need for effective interventions. Participation in mindfulness interventions has been demonstrated to reduce anxiety and depressive symptoms among teenagers. Parents' participation in mindfulness interventions has also been shown to reduce their children's mental health symptoms. However, there is no available evidence regarding potential additional benefits for adolescents' mental health of having both the adolescen... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/07/2025
Locations: Imperial High School, Imperial, California
Conditions: Child Anxiety, Depression
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
Recruiting
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: -... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Wallace Rheumatic Study Center, Beverly Hills, California
Conditions: Lupus Erythematosus, Systemic
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Recruiting
This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: City of Hope, Duarte, California
Conditions: Acute Myeloid Leukemia